Skip to main content
Clinical Trials/TCTR20220626001
TCTR20220626001
Not yet recruiting
Phase 1

Efficacy and safety of acupuncture in the treatment of pain in patients with hepatocellular carcinoma: A protocol of a randomized, single-blind, placebo-controlled clinical trial

Zhilin Zhou0 sites90 target enrollmentJune 26, 2022

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Zhilin Zhou
Enrollment
90
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 26, 2022
End Date
September 10, 2024
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Zhilin Zhou

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients who are in accordance with the diagnosis of HCC (the diagnostic criteria refer to Guidelines for diagnosis and treatment of HCC (Version 2019\)
  • 2\. Aged: 18 to 75 years old, stable and conscious;
  • 3\. Patients who have moderate and severe pain, and the 11\-point numerical rating scale (NRS) score greater than 4
  • 4\. Patients whose expected survival is greater than 6 months;
  • 5\.Patients who have strong compliance and have signed informed consent.

Exclusion Criteria

  • 1\. Patients who are accompanied by infectious diseases, diseases of blood system;
  • 2\. Patients who have history of acupuncture syncope;
  • 3\. Women in pregnancy or lactation;
  • 4\. Patients who have pain associated with causes other than HCC;
  • 5\. Skin ulceration at the needling site.

Outcomes

Primary Outcomes

Not specified

Similar Trials